BioPharma Drug Approval
Sanofi Acquires Greater China Rights for Aficamten from CORXEL, Expanding HCM Treatment Reach
Cytokinetics, Incorporated announced that Sanofi will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals (CORXEL...
December 20, 2024 | News
Hong Kong DoH Approves AGAMREE® for Duchenne Muscular Dystrophy Treatment
Department of Health (DoH) of Hong Kong approved AGAMREE® for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 4 years and older...
December 20, 2024 | News
Everest Medicines’ VELSIPITY® Prescribed in Mainland China, Pioneering New Ulcerative Colitis Treatment under Hong Kong-Macau Connect
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...
December 18, 2024 | News
Everest Medicines Announces First Prescription of VELSIPITY® for Ulcerative Colitis in Macau, Marking a Key Milestone in Asia
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing an...
December 13, 2024 | News
CureGene Secures NMPA Approval for Clinical Trial of Novel Antiplatelet Drug CG-0255 in China
CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular...
December 13, 2024 | News
Skyhawk Therapeutics Gains Australian Approval to Extend SKY-0515 Huntington’s Disease Trial to 12 Weeks
Australian Human Research Ethics Committees approves SKY-0515 treatment for up to 12 weeks in the company's ongoing Phase 1 trial in patients with Hun...
December 10, 2024 | News
Innovent and HUTCHMED Secure Conditional Approval in China for TYVYT® and ELUNATE® Combo in Advanced Endometrial Cancer
Innovent Biologics, Inc. a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of...
December 04, 2024 | News
Everest Medicines’ New Drug Application for VELSIPITY® (etrasimod) Accepted in Hong Kong for Ulcerative Colitis
Everest Medicines , a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeut...
December 03, 2024 | News
China’s 2024 National Reimbursement Drug List Expands Access to Cutting-Edge Therapies
The National Healthcare Security Administration of China has unveiled the 2024 National Reimbursement Drug List (NRDL), incorporating several pioneering th...
November 29, 2024 | News
Akeso's Penpulimab and Anlotinib Combo Accepted by NMPA for First-Line Advanced Liver Cancer Treatment
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the National Medical Products Administration (NMPA) of China has accep...
November 25, 2024 | News
Boehringer Ingelheim Introduces VETMEDIN® Solution: A Liquid Option for Managing Canine Heart Failure
Heart disease in dogs is almost as common as it is in humans, affecting approximately 10 percent of dogs in their lifetime Previous studies have shown t...
November 25, 2024 | News
Eisai Launches Rozebalamin® in Japan, Offering New Hope for ALS Patients
Eisai Co., Ltd. announced that the amyotrophic lateral sclerosis (ALS) treatment “Rozebalamin® for Injection25 mg” (mecobalamin) has ...
November 21, 2024 | News
Ractigen Therapeutics Receives FDA Orphan Drug Designation for RAG-21, a Novel siRNA Therapy for FUS-ALS
Ractigen Therapeutics, a clinical-stage pharmaceutical company dedicated to developing innovative therapies, announced that the U.S. Food and Drug Administ...
November 20, 2024 | News
Epigenic Therapeutics Secures Approval in New Zealand for World’s First Epigenetic Therapy Clinical Trial for Chronic Hepatitis B
Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy, announced that it has received appr...
November 20, 2024 | News
Most Read
- 25 Biopharma Leaders Shaping a Sustainable 2025: Innovation Meets Environmental Responsibility
- 25 Leading AI Companies to Watch in 2025: Transforming Drug Discovery and Precision Medicine
- Mr. Brendan O’Callaghan Discusses Sanofi’s Singapore Modulus Facility: Advancing Biopharma Manufacturing and Pandemic Preparedness
- Shaping the Future of PCV Care: Insights from Roche’s Stefan Scheidl on the SALWEEN Trial
- Pam Cheng Outlines AstraZeneca’s Bold Vision for Singapore’s First End-to-End ADC Manufacturing Facility
- Shaping a Health Innovation Hub: Alessandro Falcone Reflects on JLABS Singapore’s Milestone Year and Future Goals
Bio Jobs
- Avance Clinical Appoints Jessica Han as Director of Asian Operations, Strengthening Commitment to the Asian Market
- Bristol Myers Squibb Employees Cycle Coast-to-Coast to Raise $1 Million for Cancer Research
- Pfizer Australia Commits $150M to Upgrade Melbourne Facility, Bolstering Global Fight Against Antimicrobial Resistance
- SMi Systems Appoints Dr. Stefan Hamill as Vice President of Strategy to Drive Commercialisation and Growth
- Thermo Fisher Scientific Appoints William Hung as Senior Director and General Manager for Taiwan
- Cytiva Appoints Industry Veteran Pierre-Alain Ruffieux as Chief Operating Officer
News
